Table 5.
Changes in pelvic congestion syndrome symptoms assessed by the visual analog scale (VAS) in the micronized purified flavonoid fraction (MPFF, n = 42) and control (n = 41) groups
| Scale | VAS score (mean ± SD) | Change D61–D0 (mean ± SD) | P value (intra-group, Wilcoxon signed-rank test) | P value (inter-group, Mann–Whitney U test) | |
|---|---|---|---|---|---|
| Day 0 | Day 61 | ||||
| MPFF group | |||||
| Pain | 4.0 ± 3.0 | 2.0 ± 2.0 | 2.0 ± 2.2 | < 0.001 | < 0.001 |
| Heaviness | 3.1 ± 3.2 | 1.8 ± 2.3 | 1.3 ± 2.1 | < 0.001 | < 0.001 |
| Discomfort | 3.3 ± 3.4 | 1.8 ± 2.4 | 1.5 ± 2.0 | < 0.001 | < 0.001 |
| Pain in the sacrum and coccyx | 3.3 ± 3.2 | 1.9 ± 2.3 | 1.3 ± 2.4 | < 0.001 | 0.013 |
| Urination disorder | 2.4 ± 2.9 | 1.5 ± 2.0 | 1.1 ± 2.4 | < 0.001 | < 0.001 |
| Atypical varicosis | 2.3 ± 3.2 | 1.6 ± 2.5 | 0.7 ± 2.1 | 0.007 | NS |
| Dyspareunia | 3.1 ± 3.2 | 1.9 ± 2.4 | 1.3 ± 2.1 | < 0.001 | < 0.001 |
| Menstrual disorders | 1.7 ± 2.7 | 1.5 ± 2.6 | 0.2 ± 1.9 | NS | NS |
| Tenderness | 2.0 ± 2.9 | 1.1 ± 1.9 | 0.9 ± 1.9 | < 0.001 | < 0.001 |
| Edema | 2.5 ± 3.4 | 1.2 ± 1.9 | 1.3 ± 2.1 | < 0.001 | < 0.001 |
| Summary score | 27.6 ± 23.4 | 16.3 ± 18.0 | 11.6 ± 14.8 | < 0.001 | < 0.001 |
| Control group | |||||
| Pain | 4.8 ± 3.3 | 4.8 ± 3.2 | 0.0 ± 1.1 | NS | – |
| Heaviness | 4.2 ± 2.9 | 4.4 ± 3.1 | – 0.3 ± 1.0 | NS | – |
| Discomfort | 3.7 ± 2.8 | 4.1 ± 3.0 | – 0.4 ± 1.0 | 0.008 | – |
| Pain in the sacrum and coccyx | 4.2 ± 3.4 | 4.0 ± 3.1 | 0.2 ± 1.0 | NS | – |
| Urination disorder | 2.3 ± 3.2 | 2.3 ± 3.2 | – 0.1 ± 1.0 | NS | – |
| Atypical varicosis | 2.2 ± 3.1 | 2.0 ± 2.9 | 0.49 ± 1.2 | NS | – |
| Dyspareunia | 4.3 ± 3.7 | 4.4 ± 3.5 | – 0.1 ± 1.2 | NS | – |
| Menstrual disorders | 2.8 ± 3.4 | 3.0 ± 3.4 | – 0.1 ± 1.1 | NS | – |
| Tenderness | 2.4 ± 3.1 | 2.9 ± 3.3 | – 0.5 ± 1.3 | 0.019 | – |
| Edema | 2.2 ± 3.1 | 2.5 ± 3.1 | – 0.3 ± 1.1 | NS | – |
| Summary score | 33.1 ± 22.2 | 34.5 ± 23.6 | – 1.0 ± 5.2 | NS | – |